Altoida Board Boost: Ignite Your Neuro Sales Pipeline

🚀 Battle Card: Altoida

• Mona Flores, MD, Clinical and Scientific Advisory Board Member · 🔗 [LinkedIn](https://www.linkedin.com/company/altoida/)

• Bryan J. Hansen, PhD, Clinical and Scientific Advisory Board Member · 🔗 [LinkedIn](https://www.linkedin.com/company/altoida/)

• Michael Zuendel, Clinical and Scientific Advisory Board Member · 🔗 [LinkedIn](https://www.linkedin.com/company/altoida/)

• New board members bring AI, pharma launch, and patient advocacy expertise to fast-track clinical adoption of a category-defining neurodiagnostic. → Source

• Leverage this Altoida sales trigger to position your pitch around their pivotal FDA submission and pharma partnerships.

• Slow, subjective cognitive assessments hinder early diagnosis.

• Lack of patient-centric tools limits adoption and engagement.

• Primary: Digital NeuroMarker Platform → 10-minute, self-administered early detection of cognitive impairment

• Expansion: AI/AR integration services → accelerate clinical trials and enhance patient advocacy impact

• HQ: Washington, DC

• Employees: ≈ 75

• Rev: ≈ $10 M

• Website: [altoida.com](https://www.altoida.com/)

🤼 Competitive Intel

• Cogstate — Cognitive Assessment
• Unique edge: Extensive neuropsychological test library
• Evaluated by VP Ops for clinical trial efficiency

• BrainCheck — Digital Cognitive Health
• Unique edge: FDA-listed mobile app for remote testing
• Evaluated by Dir. of Research for patient engagement

• Cambridge Cognition — Neuro Assessments
• Unique edge: Peer-reviewed biomarker algorithms
• Evaluated by Chief Medical Officer for scientific rigor

• GrayMatter Technologies — Neural Data Analytics
• Unique edge: Real-time neural signal processing
• Evaluated by CTO for integration flexibility

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑≈ TBD❑
OFFER_BRIEF   = ❑10-minute, self-administered digital cognitive assessments❑
PROOF_METRIC  = ❑20+ years of research and 42K tests❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Mona
COMPANY     = Altoida
DEPT        = Clinical and Scientific Advisory
SIZE        = ≈ TBD
BOTTLENECK  = manual, subjective assessments hinder scalability
EVENT       = Expands Advisory Board with Global Leaders in AI, Pharma, and Alzheimer’s Patient Advocacy
DETAIL      = appointment of three new advisory board members
PAIN        = slow, subjective cognitive assessments hinder early diagnosis
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251007367972&div=41152219
SIM_CO      = Cogstate
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = ≈ TBD
EMP_EST     = ≈ 75
REV_EST     = ≈ $10 M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈ TBD-person Clinical and Scientific Advisory

Mona—noticed your Clinical and Scientific Advisory team is ≈ TBD.

That’s when manual, subjective assessments hinder scalability.

We helped Cogstate fix this with 10-minute, self-administered digital cognitive assessments.

Result: ≈ TBD.  
Quick call?

PS—next bottleneck hits ≈ TBD.

DM ≤45 words, TONE:
Saw your post about appointment of three new advisory board members — slow, subjective cognitive assessments hinder early diagnosis.  
10-minute, self-administered digital cognitive assessments. 20+ years of research and 42K tests.  
Quick chat?